Clinician’s Experience Enhances Melanoma Detection with Nevisense

Published

4 months ago

5 March, 2026

On March 5, 2026, SciBase Holding AB, a prominent developer of AI-based diagnostic solutions for skin disorders, announced the publication of a clinical article by Stephen D. Hess, MD, PhD, FAAD. The article, featured in The Dermatologist, discusses the real-world integration of Nevisense into routine melanoma detection practices.

Advancing Melanoma Detection

Dr. Hess’s publication highlights how Nevisense provides objective data that complements traditional visual examinations and dermoscopy. This technology is particularly valuable when assessing atypical pigmented lesions, allowing for enhanced risk stratification in challenging clinical cases. “In everyday practice, many pigmented lesions fall into a diagnostic gray zone,” Dr. Hess stated. “Nevisense adds objective, real-time information beneath the skin’s surface, enhancing clinical judgment and supporting more accurate biopsy decisions.”

The significance of Nevisense is underscored by the rising incidence of melanoma, prompting a need for reliable technology that delivers actionable data. Pia Renaudin, CEO of SciBase, emphasized the importance of such objective technologies, stating, “Dr. Hess’s publication in The Dermatologist highlights the growing importance of objective technologies like Nevisense in advancing melanoma detection and improving patient outcomes.”

About Nevisense and SciBase

SciBase is recognized as a global medical technology leader, specializing in early detection and prevention in dermatology. Nevisense, the company’s innovative point-of-care platform, combines artificial intelligence and advanced electrical impedance spectroscopy (EIS) technology to enhance diagnostic accuracy. With over 20 years of research originating from the Karolinska Institute in Stockholm, SciBase aims to minimize patient suffering through timely detection and intervention.

The company has been publicly traded on the Nasdaq First North Growth Market since June 2, 2015. For additional information, visit www.scibase.com or access press releases and financial reports at http://investors.scibase.se/en/pressreleases.

For further inquiries, media representatives can contact: Pia Renaudin, CEO at +46 73 206 98 02 or via email at [email protected].

Related Topics:

Up Next

Apollo Launches #CheckForChange Campaign to Empower Women’s Health

Don't Miss

Gold Prices Surge: What Would King Tut Choose Today?

Editorial

Our Editorial team doesn’t just report the news—we live it. Backed by years of frontline experience, we hunt down the facts, verify them to the letter, and deliver the stories that shape our world. Fueled by integrity and a keen eye for nuance, we tackle politics, culture, and technology with incisive analysis. When the headlines change by the minute, you can count on us to cut through the noise and serve you clarity on a silver platter.